Discipline before instinct.
Think with me, not just trade with me.
No stock tips, no hype calls. Every judgment runs through the same repeatable process: first filter out what should never be touched, then decide how to enter and how to control risk. You see the conclusion — and every step of the reasoning.
Positioning, moat, volatility, technicals — filtered in order. First ask "should I touch this at all", then "how do I enter".
Institutional strength, relative strength and earnings quality quantified into a reviewable verdict — not a gut call.
Stock selection, options selling and financial-statement analysis — each track runs from concept to executable SOP.
Three Learning Tracks
Full curriculum →Stock selection, options selling, financial analysis. Each track goes from concepts and tools to executable SOPs.
Super Performance Stock Selection
Built on Mark Minervini’s SEPA methodology, integrating CANSLIM with technical entry execution — from why to buy strength to when to buy, sell, and how much.
Options Selling System
Probability-first: from seller philosophy and core tools to full strategy SOP and risk management — a cash-flow framework that puts time on your side.
Financial Statement Analysis
The intro track teaches you to read the three statements, footnotes and earnings calls; the advanced series teaches you to see through them — CPA audit lens, CFA quality frameworks, and AI-assisted screening.
This Week’s Screen Signals
Updated 2026-09-11Verdicts from the Four-Layer Defensive Screen, reasoning included.
Latest Research
Astera Labs (ALAB) September Reassessment: Every Metric Passed, the Stock Fell 43% — the Company Didn't Fail the Test, the Market Changed the Exam
Astera Labs passed all seven Q2 checks with zero invalidation triggers, yet the stock is down 43% from its high and fell another 11.5% over four weeks with no news. Peer Credo grew revenue 115% and still lost a third in 30 days; PV Rating A/D is E, RS is 62. Nothing broke — the money left. We test three hypotheses, rebuild the valuation matrix, and add the flow-of-funds axis the August framework was missing.
NVIDIA's Third Growth Curve: Three Businesses Not Yet Visible in Its Financials
Autonomous driving, AI drug discovery, and robotics—three businesses grouped under the Edge Computing segment—accounted for just 7.5% of NVIDIA's revenue in FY27Q2 and contributed virtually nothing to EPS over the past two years, yet they will determine its valuation multiple beyond FY2030. This article values each business through an options framework while taking an unvarnished view of AI drug development: zero approvals globally, even as NVIDIA has fully exited its stake in Recursion. The company selling the picks and shovels is not betting on the gold mine.
NVIDIA's Golden Decade: Is Taiwan Capturing Revenue or Profit?
Taiwan is not merely an NVIDIA supplier; it is NVIDIA's production capacity itself. But gains cannot be judged by gross margin alone—Wiwynn posted a single-digit gross margin, yet its full-year 2025 ROE reached 48.03%; Hon Hai had a similar gross margin, but ROE was only 11.08%. Using three ROE engines, this article identifies which Taiwan supply-chain players are truly capturing the returns from NVIDIA's golden decade.
NVIDIA (NVDA) Deep Dive: Shares Near a Record High, Yet the P/E Is Just 22x—What Is the Market Afraid Of?
The market is willing to believe NVIDIA’s earnings are real, yet refuses to award the company a growth-stock multiple. With DSO lengthening by 15 days in one quarter, the top five customers accounting for 70% of receivables, and upstream supply commitments reaching $279 billion, this initiation report asks whether those earnings can withstand the next phase of capital-spending digestion.